SION: SION-451 + SION-2222 will advance to Phase 2a after analysis supports NBD1 activity
Post hoc analysis of the PreciSION CF trial revealed confounding factors but supported NBD1 biological activity, leading to the advancement of SION-451 + SION-2222 into a Phase 2a trial. Cost-saving measures, including a 46% workforce reduction, will extend the cash runway into 2029.Original docume…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.